Role of versican, hyaluronan and CD44 in ovarian cancer metastasis

Int J Mol Sci. 2011 Jan 31;12(2):1009-29. doi: 10.3390/ijms12021009.

Abstract

There is increasing evidence to suggest that extracellular matrix (ECM) components play an active role in tumor progression and are an important determinant for the growth and progression of solid tumors. Tumor cells interfere with the normal programming of ECM biosynthesis and can extensively modify the structure and composition of the matrix. In ovarian cancer alterations in the extracellular environment are critical for tumor initiation and progression and intra-peritoneal dissemination. ECM molecules including versican and hyaluronan (HA) which interacts with the HA receptor, CD44, have been shown to play critical roles in ovarian cancer metastasis. This review focuses on versican, HA, and CD44 and their potential as therapeutic targets for ovarian cancer.

Keywords: CD44; adhesion; extracellular matrix; hyaluronan; metastasis; versican.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carcinoma / drug therapy
  • Carcinoma / metabolism*
  • Carcinoma / pathology
  • Carcinoma / secondary*
  • Female
  • Humans
  • Hyaluronan Receptors / genetics
  • Hyaluronan Receptors / metabolism*
  • Hyaluronic Acid / metabolism*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / metabolism*
  • Ovarian Neoplasms / pathology
  • Paclitaxel / therapeutic use
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / metabolism
  • Peritoneal Neoplasms / secondary*
  • Versicans / genetics
  • Versicans / metabolism*

Substances

  • Antineoplastic Agents
  • Hyaluronan Receptors
  • Versicans
  • Hyaluronic Acid
  • Paclitaxel